Therapeutic Asset Ratings

831 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Doxycycline Diabetes Mellitus	Mayo Clinic	P4	B (61)
FILGRASTIM Endometrial Carcinoma	Mayo Clinic	P3	B (61)
Acalabrutinib Richter Transformation	Mayo Clinic	P2	B (61)
Cyclophosphamide Fallopian Tube Carcinosarcoma	Mayo Clinic	P2	B (61)
CARVEDILOL Lymphoma	Mayo Clinic	P3	B (60)
Dabrafenib Metastatic Melanoma	Mayo Clinic	P3	B (60)
Methylene Blue Cancer	Mayo Clinic	P3	B (60)
Olanzapine Hematopoietic And Lymphoid Cell Neoplasm	Mayo Clinic	P3	B (60)
OTL-38 Childhood Malignant Neoplasm	Mayo Clinic	P3	B (60)
OTL-38 Childhood Malignant Thoracic Neoplasm	Mayo Clinic	P3	B (60)
OTL-38 Malignant Abdominal Neoplasm	Mayo Clinic	P3	B (60)
OTL-38 Malignant Tumor Of Neck	Mayo Clinic	P3	B (60)
Cyclophosphamide ALK-Positive Large B-Cell Lymphoma	Mayo Clinic	P2	B (60)
Cyclophosphamide Recurrent Glioblastoma, IDH-Wildtype	Mayo Clinic	P2	B (60)
Epirubicin Fallopian Tube Clear Cell Adenocarcinoma	Mayo Clinic	P2	B (60)
Epirubicin Gliosarcoma	Mayo Clinic	P2	B (60)
Epirubicin Ovarian Carcinosarcoma	Mayo Clinic	P2	B (60)
Epirubicin Recurrent Glioblastoma, IDH-Wildtype	Mayo Clinic	P2	B (60)
FILGRASTIM Intrahepatic Cholangiocarcinoma	Mayo Clinic	P2	B (60)
FLUTICASONE Breast Adenocarcinoma	Mayo Clinic	P2	B (60)
Golcadomide Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Mayo Clinic	P2	B (60)
Golcadomide High Grade B-Cell Lymphoma	Mayo Clinic	P2	B (60)
Golcadomide Primary Mediastinal Large B-Cell Lymphoma	Mayo Clinic	P2	B (60)
Ibrutinib Cutaneous Melanoma	Mayo Clinic	P2	B (60)
Ibrutinib Stage IV Cutaneous Melanoma AJCC v6 and v7	Mayo Clinic	P2	B (60)

Showing 176 to 200 of 831 assets